Of the three types of MS, PPMS is considered the rarest, affecting 10% of people living with MS. As with other forms of MS, ...

Other MS patients, a minority, have a form of the disease that features gradually increasing progressive disability from onset—so-called primary progressive MS (PPMS). While effective disease ...

This exploratory study assessed the safety and clinical benefit of masitinib in the treatment of primary progressive MS (PPMS) or relapse-free secondary progressive MS (rfSPMS). Methods ...

National Multiple Sclerosis Society: "FDA Approves Ocrevus™ (ocrelizumab) for People with Primary Progressive MS or Relapsing MS -- First Disease-Modifying Therapy for Primary Progressive MS ...

Sanofi is also running a fourth phase 3 trial called PERSEUS in patients with primary progressive MS (PPMS). Earlier this year, it abandoned its development in another neuromuscular disorder ...

clinically isolated syndrome relapsing-remitting MS secondary progressive MS primary progressive MS There’s no one set timeline or course of MS, but knowing the type can help you understand and ...

Clinically isolated syndrome Relapsing remitting MS Secondary progressive MS Primary progressive MS You get ocrelizumab through an infusion into your vein in a doctor’s office or clinic.

Higher blood levels of bile acids, molecules that aid fat absorption in the gut, are linked to slower MS progression, per ...

A new drug for people who have one of the worst forms of multiple sclerosis aims to make treatment much easier for patients. Ocrevus is a medicine commonly used to treat primary progressive MS ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare ...

In its first draft guidance, NICE said that Ocrevus (ocrelizumab) is not cost-effective in primary progressive multiple sclerosis (PPMS). The cost-effectiveness body noted clinical trial evidence ...

The phase III PERSEUS trial is evaluating tolebrutinib in primary progressive MS, with results expected in 2025. This research was funded by Sanofi. Fox reported relationships with AB Science ...